Logo
x

Search

Subscribe Now

eosinophilic esophagitis

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Eosinophilic Esophagitis

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Eosinophilic Esophagitis

  • October 25, 2021
PharmaShots Interview: Revolo's Jonathan Rigby Shares Insights on the ‘1104 for Eosinophilic Esophagitis

PharmaShots Interview: Revolo's Jonathan Rigby Shares Insights on the ‘1104 for Eosinophilic Esophagitis

  • August 18, 2021
Sanofi and Regeneron Report Results of Dupixent (dupilumab) in Part A of P-lll Study for Eosinophilic Esophagitis (EoE)

Sanofi and Regeneron Report Results of Dupixent (dupilumab) in Part A of P-lll Study for Eosinophilic Esophagitis (EoE)

  • October 27, 2020
Sanofi's Dupixent Receives the US FDA's Breakthrough Therapy Designation for Eosinophilic Esophagitis

Sanofi's Dupixent Receives the US FDA's Breakthrough Therapy Designation for Eosinophilic Esophagitis

  • September 14, 2020
Sanofi and Regeneron Report Positive Results of Dupixent (dupilumab) in P-IIIa Dupixent Eosinophilic Esophagitis Study for EoE

Sanofi and Regeneron Report Positive Results of Dupixent (dupilumab) in P-IIIa Dupixent Eosinophilic Esophagitis Study for EoE

  • May 25, 2020
Lucid Diagnostics Collaborates with the University of Pennsylvania to Evaluate EsoCheck in Patients with Eosinophilic Esophagitis

Lucid Diagnostics Collaborates with the University of Pennsylvania to Evaluate EsoCheck in Patients with Eosinophilic Esophagitis

  • March 3, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.